Evidence map›Paper›PMID 37872229›Full record

ArticleNature communications2023

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch and 13 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 4 countries.

Othman Al-SawafFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. othman.al-sawaf@uk-koeln.de.ORCID http://orcid.org/0000-0001-9895-0570
Can ZhangFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Hyun Yong JinGenentech Inc., South San Francisco, CA, USA.
Sandra RobrechtFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Yoonha ChoiGenentech Inc., South San Francisco, CA, USA.
Sandhya BalasubramanianGenentech Inc., South San Francisco, CA, USA.
Alex KotakRoche Products Ltd, Welwyn Garden City, UK.
Yi Meng ChangHoffmann-la Roche, Mississauga, ON, Canada.
Anna Maria FinkFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Eugen TauschDepartment III of Internal Medicine, Ulm University, Ulm, Germany.
Christof SchneiderDepartment III of Internal Medicine, Ulm University, Ulm, Germany.
Matthias RitgenDepartment II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany.
Karl-Anton KreuzerFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Brenda ChylaAbbVie Inc., North Chicago, IL, USA.
Joseph N PaulsonGenentech Inc., South San Francisco, CA, USA.
Christian P PallaschFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0001-5675-6905
Lukas P FrenzelFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Martin PeiferFaculty of Medicine and University Hospital Cologne, Department of Translational Genomics, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-5243-5503
Barbara EichhorstFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Stephan StilgenbauerDepartment III of Internal Medicine, Ulm University, Ulm, Germany.ORCID http://orcid.org/0000-0002-6830-9296
Yanwen JiangGenentech Inc., South San Francisco, CA, USA.
Michael HallekFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. michael.hallek@uni-koeln.de.ORCID http://orcid.org/0000-0002-7425-4455
Kirsten FischerFaculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. kirsten.fischer@uk-koeln.de.ORCID http://orcid.org/0009-0006-6169-9152
University of Cologne · DEUniversität Ulm · DEAbbVie (United States) · USChristian-Albrechts-Universität zu Kiel · DERoche (Canada) · CARoche (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37872229
PMCPMC10593794
OpenAlexW4387873763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.